Neonatal SARS-CoV-2 immunoglobulin G antibodies at delivery and their impact on COVID-19.

Publication date: Feb 07, 2024

To assess neonatal SARS-CoV-2 anti-spike IgG antibody levels after maternal mRNA COVID-19 vaccination and/or infection during pregnancy and evaluate their protective effect. Prospective observational study, conducted from January 2021 to December 2022. Infants were tested for anti-spike IgG antibodies at birth and then every 3 months until disappearance of titer. A follow-up was done for SARS-CoV-2 infection up to 12 months. In total, 147 newborns were enrolled with a median (IQR) gestational age of 39. 60 weeks (38. 3-40. 4). Median (IQR) titers in UA/ml at 2 days were higher (P 

Concepts Keywords
3months Anti-spike IgG antibodies
Antibodies COVID-19
December Immunity
Neonatal mRNA COVID-19 vaccination
Vaccination Newborn


Type Source Name
disease MESH COVID-19
disease VO vaccination
disease MESH infection
disease VO titer
pathway REACTOME SARS-CoV-2 Infection

Original Article

(Visited 1 times, 1 visits today)